92 related articles for article (PubMed ID: 2998083)
41. Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor.
Iwasaki A; Shirakusa T; Yoshinaga Y; Enatsu S; Yamamoto M
Eur J Cardiothorac Surg; 2004 Sep; 26(3):488-93. PubMed ID: 15302040
[TBL] [Abstract][Full Text] [Related]
42. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
[TBL] [Abstract][Full Text] [Related]
43. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
44. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
[TBL] [Abstract][Full Text] [Related]
45. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
46. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
47. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension.
Okada M; Sakamoto T; Nishio W; Uchino K; Tsubota N
Cancer; 2003 Aug; 98(3):535-41. PubMed ID: 12879471
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
49. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.
Viñolas N; Molina R; Galán MC; Casas F; Callejas MA; Filella X; Grau JJ; Ballesta AM; Estape J
Anticancer Res; 1998; 18(1B):631-4. PubMed ID: 9584045
[TBL] [Abstract][Full Text] [Related]
50. Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma.
Picardo AL; Diez M; Torres A; Maestro M; Ortega D; Hernando F; Gómez A; Garcia-Asenjo J; Balibrea JL
Cancer; 1996 Mar; 77(6):1066-72. PubMed ID: 8635125
[TBL] [Abstract][Full Text] [Related]
51. A study of immunoreactive calcitonin (CT), adrenocorticotropic hormone (ACTH) and carcinoembryonic antigen (CEA) in lung cancer and other malignancies.
Krauss S; Macy S; Ichiki AT
Cancer; 1981 May; 47(10):2485-92. PubMed ID: 6268270
[TBL] [Abstract][Full Text] [Related]
52. Recent advances in the treatment of small cell lung cancer.
Hosker HS; Veale D; Corris PA
Br J Hosp Med; 1989 Aug; 42(2):129-32. PubMed ID: 2548648
[TBL] [Abstract][Full Text] [Related]
53. [Main indicators of hormonal status in lung diseases].
Zyrianov BN; Velichko SA; Kuznetsov VV; Siianov VS
Med Radiol (Mosk); 1988 Aug; 33(8):31-4. PubMed ID: 2842572
[TBL] [Abstract][Full Text] [Related]
54. [Use of non-traditional methods of examination in the differential diagnosis of cancer and tuberculosis of the lungs].
Moroz GS; Dykan IN; Volkova LA; Savula MM; Piatnochko IT
Klin Khir (1962); 1989; (10):9-12. PubMed ID: 2559239
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic and therapeutic implications of ectopic hormone production in small cell carcinoma of the lung.
Hansen M; Hammer M; Hummer L
Thorax; 1980 Feb; 35(2):101-6. PubMed ID: 6246651
[TBL] [Abstract][Full Text] [Related]
56. Urinary polyamines for evaluating the course of disease for patients with small cell carcinoma of the lung.
Woo KB; Waalkes TP; Abeloff MD; Lenhard RE; Gehrke CW; Kuo KC
Cancer; 1983 Nov; 52(9):1684-90. PubMed ID: 6311401
[TBL] [Abstract][Full Text] [Related]
57. Carcinoembryonic antigen, arginine vasopressin and calcitonin as markers of early small-cell lung cancer relapse.
Biran H; Feld R; Sagman U; Rusthoven J; Shepherd FA; Evans WK; Ginsberg RJ; Panzarella T; Malkin A
Tumour Biol; 1989; 10(5):258-67. PubMed ID: 2554479
[TBL] [Abstract][Full Text] [Related]
58. Tumor markers in patients with lung cancer.
Hansen M; Pedersen AG
Chest; 1986 Apr; 89(4 Suppl):219S-224S. PubMed ID: 3007040
[TBL] [Abstract][Full Text] [Related]
59. [Cortisol content in the blood plasma in lung cancer].
Uspenskaia LP; Medvedev VN; Firsova PP
Vopr Onkol; 1978; 24(10):58-61. PubMed ID: 716319
[TBL] [Abstract][Full Text] [Related]
60. Plasma calcitonin as a marker of disease activity in patients with small cell carcinoma of the lung.
Wallach SR; Royston I; Taetle R; Wohl H; Deftos LJ
J Clin Endocrinol Metab; 1981 Sep; 53(3):602-6. PubMed ID: 6267098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
